IP Verse

Subcutaneous Formulations Of Anti-Cd38 Antibodies And Their Uses - EP3827845

The patent EP3827845 was granted to Janssen Biotech on Mar 30, 2022. The application was originally filed on Nov 1, 2016 under application number EP20215879A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3827845

JANSSEN BIOTECH
Application Number
EP20215879A
Filing Date
Nov 1, 2016
Status
Granted And Under Opposition
Feb 25, 2022
Grant Date
Mar 30, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (6)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

STORZDec 29, 2022MICHALSKI HUTTERMANN & PARTNER PATENTANWALTE MBBADMISSIBLE
PATENT BOUTIQUEDec 29, 2022PATENT BOUTIQUEWITHDRAWN
KONIG SZYNKA TILMANN VON RENESSEDec 27, 2022KONIG SZYNKA TILMANN VON RENESSE PATENTANWALTE PARTNERSCHAFT MBB DUSSELDORFADMISSIBLE
DR H ULRICH DORRIESDec 22, 2022DORRIESADMISSIBLE
DR H ULRICH DORRIESDec 22, 2022DORRIES, HANS ULRICH , DF-MP DORRIES FRANK-MOLNIA & POHLMANADMISSIBLE
XBRANE BIOPHARMADec 21, 2022YILDIRIMADMISSIBLE

Patent Citations (75) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS2007287170
DESCRIPTIONUS2009182127
DESCRIPTIONUS2010015133
DESCRIPTIONUS2010286374
DESCRIPTIONUS2011123532
DESCRIPTIONUS2012149876
DESCRIPTIONUS4683195
DESCRIPTIONUS5223409
DESCRIPTIONUS5403484
DESCRIPTIONUS5427908
DESCRIPTIONUS5571698
DESCRIPTIONUS5580717
DESCRIPTIONUS5885793
DESCRIPTIONUS5932448
DESCRIPTIONUS5969108
DESCRIPTIONUS6172197
DESCRIPTIONUS6521404
DESCRIPTIONUS6544731
DESCRIPTIONUS6555313
DESCRIPTIONUS6582915
DESCRIPTIONUS6593081
DESCRIPTIONUS6737056
DESCRIPTIONUS6833441
DESCRIPTIONUS7695936
DESCRIPTIONUS7767429
DESCRIPTIONUS7829693
DESCRIPTIONUS8088896
DESCRIPTIONUS8153765
DESCRIPTIONWO2004078140
DESCRIPTIONWO2004111233
DESCRIPTIONWO2005103083
DESCRIPTIONWO2006125640
DESCRIPTIONWO2007042309
DESCRIPTIONWO2008047242
DESCRIPTIONWO2008077546
DESCRIPTIONWO2008119353
DESCRIPTIONWO2009085462
DESCRIPTIONWO2009134776
DESCRIPTIONWO2011131746
DESCRIPTIONWO2011143545
DESCRIPTIONWO2012022811
DESCRIPTIONWO2014178820
DESCRIPTIONWO8801649
DESCRIPTIONWO9201047
DESCRIPTIONWO9413804
DESCRIPTIONWO9844001
OPPOSITIONAU2013200711
OPPOSITIONEP2459167
OPPOSITIONEP2477603
OPPOSITIONEP3370770
OPPOSITIONUS2010074885
OPPOSITIONUS2011053247
OPPOSITIONUS2011066111
OPPOSITIONUS2011076273
OPPOSITIONUS2013022588
OPPOSITIONUS2015118251
OPPOSITIONUS2015231235
OPPOSITIONUS250016
OPPOSITIONUS8318154
OPPOSITIONWO2004078140
OPPOSITIONWO2007005608
OPPOSITIONWO2008037257
OPPOSITIONWO2008150949
OPPOSITIONWO2010087972
OPPOSITIONWO2010102251
OPPOSITIONWO2011012637
OPPOSITIONWO2011029892
OPPOSITIONWO2012064627
OPPOSITIONWO2013102144
OPPOSITIONWO2014105810
OPPOSITIONWO2015100366
OPPOSITIONWO2016187546
OPPOSITIONWO2016209921
OPPOSITIONWO2017079150
SEARCHUS2015118251

Non-Patent Literature (NPL) Citations (114) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- CHIARUGI et al., Nature Reviews, (20120000), vol. 12, pages 741 - 52
DESCRIPTION- CHOTHIALESK, Mol Biol, (19870000), vol. 196, pages 901 - 17
DESCRIPTION- FERRARA et al., Biotechnol Bioeng, (20060000), vol. 93, pages 851 - 861
DESCRIPTION- FERRARA et al., J Biol Chem, (20060000), vol. 281, pages 5032 - 5036
DESCRIPTION- FUNARO et al., J Immunol, (19900000), vol. 145, pages 2390 - 6
DESCRIPTION- "GenBank", Database accession no. NP 001766
DESCRIPTION- GUSE et al., Nature, (19990000), vol. 398, pages 70 - 3
DESCRIPTION- HOOGENBOOMWINTER, J Mol Biol, (19910000), vol. 222, page 581
DESCRIPTION- KNAPPIK et al., J Mol Biol, (20000000), vol. 296, pages 57 - 86
DESCRIPTION- KONNO et al., Cytotechnology, (20120000), vol. 64, pages 249 - 65
DESCRIPTION- KREBS et al., J Immunol Meth, (20010000), vol. 254, pages 67 - 84
DESCRIPTION- LEFRANC et al., Dev Comparat Immunol, (20030000), vol. 27, pages 55 - 77
DESCRIPTION- MACLENNAN et al., Acta Physiol Scand Suppl, (19980000), vol. 643, pages 55 - 67
DESCRIPTION- MAHJ et al., Exp Toxicol Path, (20060000), vol. 57, pages 341 - 5
DESCRIPTION- MORI et al., Biotechnol Bioeng, (20040000), vol. 88, pages 901 - 908
DESCRIPTION- OLIVIER et al., MAbs, (20100000), vol. 2, no. 4
DESCRIPTION- SASAKI et al., Adv Biophys, (19980000), vol. 35, pages 1 - 24
DESCRIPTION- SHEETS, PITAS (USA, (19980000), vol. 95, pages 6157 - 6162
DESCRIPTION- SHIELDS et al., J Biol Chem, (20020000), vol. 277, pages 26733 - 26740
DESCRIPTION- SHI et al., J Mol Biol, (20100000), vol. 397, pages 385 - 96
DESCRIPTION- SHI et al., J. Mol. Biol., (20100000), vol. 397, pages 385 - 96
DESCRIPTION- SHINKAWA et al., J Biol Chem, (20030000), vol. 278, pages 3466 - 3473
DESCRIPTION- TERHORST et al., Cell, (19810000), pages 771 - 80
DESCRIPTION- VAUGHAN et al., Nature Biotechnology, (19960000), vol. 14, pages 309 - 314
DESCRIPTION- WUKABAT, J Exp Med, (19700000), vol. 132, pages 211 - 50
DESCRIPTION- XHOU et al., Biotechnol Bioeng, (20080000), vol. 99, pages 652 - 65
OPPOSITION- Anonymous, "Assessment report Mabthera International non-proprietary name: RITUXIMAB Procedure No. EMEA/ H/C/ 000165/ X/ 0083", EUROPEAN MEDICINES AGENCY EMA/CHMP/71722/2014, (2014), pages 1 - 103, XP055858066
OPPOSITION- Anonymous, "CHMP assessment report: Gazyvaro", EUROPEAN MEDICINES AGENCY, (20140522), pages 1 - 123, EUROPEAN MEDICINES AGENCY, URL: https://www.ema.europa.eu/en/documents/assessment-report/gazyvaro-epar-public-assessment-report_en.pdf, (20210212), XP055775523
OPPOSITION- Anonymous, "CHMP assessment report Herceptin International non-proprietary name trastuzumab Procedure No. EMEA/ H/ C/ 000278", European Medicines Agency / EMA/CHMP/751770/2012/corr1, (20130627), pages 1 - 70, XP055858060
OPPOSITION- Anonymous, "Common Terminology Criteria for Adverse Events v 4.0 (C T C A E)", U.S.DEPARTMENT OF HEALTH AND HUMAN SERVICES, (20090528), U.S.DEPARTMENT OF HEALTH AND HUMAN SERVICES , (20230112), XP093013269
OPPOSITION- Anonymous, "EMA SOPC of Rituximab", EMA, (20210000), pages 1 - 153, XP093013772
OPPOSITION- Anonymous, "EU CLINICAL TRIALS REGISTER", Gernany, Gernany, (20150130), (20230109), XP093012462
OPPOSITION- Anonymous, " Halozyme Therapeutics Reports Selection Of First Product Candidate Under Janssen Collaboration", Halozyme Therapeutics, (20150310), pages 1 - 4, Halozyme Therapeutics, URL: http://halozyme2015.q4web.com/investors/news-releases/news-release-details/2015/Halozyme-Therapeutics-Reports-Selection-Of-First-Product-Candidate-Under-Janssen-Collaboration/default.aspx, (20211104), XP055858046
OPPOSITION- Anonymous, "History of Changes for Study: NCT02519452 A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma", ClinicalTrials.gov, (20150806), pages 1 - 12, XP055856922
OPPOSITION- Anonymous, "History of Changes for Study: NCT02519452 A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma", Clinicaltrials.gov NCT02519452, (20160806), pages 1 - 6, XP093013758
OPPOSITION- Anonymous, "Hylenex prescribing information", NDA, (20120101), NDA , (20230109), XP093012139
OPPOSITION- Anonymous, "International Nonproprietary Names for Pharmaceutical Substances (INN)", WHO Drug Information, (20090101), vol. 23, no. 2, pages 129 - 192, XP055858023
OPPOSITION- Anonymous, "Mabthera - CHMP assessment report", European Medicines Agency, (20140123), pages 1 - 103, European Medicines Agency, (20211104), XP055857967
OPPOSITION- Anonymous, "NCT02519452 clinical trials study", clinicaltrials.gov, (20150101), clinicaltrials.gov, (20230109), XP093012432
OPPOSITION- Anonymous, "Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis", (20081007), pages 1 - 8, Clinicaltrials, URL: https://clinicaltrials.gov/study/NCT00727194?tab=history&a=3, (20231010), XP093090185
OPPOSITION- BAUER et al., "Lehrbuch der Pharma- zeutischen Technologie", Wissenschaftliche Verlagsgesellschaft mbH, (20060000), vol. 9, pages 238 - 243, XP093013789
OPPOSITION- BAUER et al., "Lehrbuch der Pharmazeutischen Technologie", Wissenschaftliche Verlagsgesellschaft, Stuttgart, (20060000), pages 238 - 243
OPPOSITION- Bittner B; Richter W F; Hourcade-Potelleret F; Mcintyre C; Herting F; Zepeda M L; Schmidt J, "Development of a subcutaneous formulation for trastuzumab - nonclinical and clinical bridging approach to the approved intravenous dosing regimen", Arzneimittelforschung, (20120000), vol. 62, pages 401 - 409, XP055824302
OPPOSITION- Bittner B., W. F. Richter, F. Hourcade-Potelleret, C. Mcintyre, F. Herting, M. L. Zepeda, J. Schmidt, "Development of a Subcutaneous Formulation for Trastuzumab - Nonclinical and Clinical Bridging Approach to the Approved Intravenous Dosing Regimen", ARZNEIMITTELFORSCHUNG, (20120101), vol. 62, pages 401 - 409, XP055824302
OPPOSITION- CHARI, A. et al., "Subcutaneous Delivery of Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): PAVO, an Open-label, Multicenter, Dose Escalation Phase 1 b Stud", American Society of Hematology (ASH) Presentation
OPPOSITION- Dominique Leveque, "Subcutaneous Administration of Anticancer Agents", Anticancer Research, (20140401), vol. 34, pages 1579 - 1586, XP055344175
OPPOSITION- Ema, "Mabthera (rituximab)", CHMP Assessment Report EMEA/H/C/000165/X/0083, (20140123), pages 1 - 103, CHMP Assessment Report EMEA/H/C/000165/X/0083, (20230111), XP093012922
OPPOSITION- Eva-Maria Ruberg, Wolfgang Frieß, "Proteinarzneistoffe: Sensibel und stressanfällig | PZ - Pharmazeutische Zeitung", (20111209), pages 1 - 15, URL: https://www.pharmazeutische-zeitung.de/ausgabe-502011/sensibel-und-stressanfaellig/, (20211102), XP055856931
OPPOSITION- Fda, "Darzalex ", Highlights of prescribing information, (20151101), pages 1 - 24, Highlights of prescribing information, (20230111), XP093012919
OPPOSITION- Fda, "Herceptin (trastuzumab)", CHMP Assessment Report EMEA/H/C/000278, (20130627), pages 1 - 70, CHMP Assessment Report EMEA/H/C/000278, (20230111), XP093012933
OPPOSITION- HALLER MF, "Converting intravenous dosing to subcutaneous dosing: With recombinant human hyaluronidase", Pharmaceutical Technology, (20070000), vol. 31, no. 10, pages 118 - 132, XP009122858
OPPOSITION- HALLER, M.F., "Converting intravenous '' dosing to subcutaneous dosing: With recombinant", Pharmaceutical Technology, (20070000), vol. 31, no. 10, pages 118 - 132, XP009122858
OPPOSITION- Hoffmann-La Roche, "NCT00950300 | A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer", ClinicalTrials.gov, NLM, (20160301), pages 1 - 23, ClinicalTrials.gov, URL: https://clinicaltrials.gov/study/NCT00950300?tab=history&a=126#version-content-panel, XP093209064
OPPOSITION- Hydase label
OPPOSITION- Janssen Research & Development, Llc, "Daratumumab (HuMax -CD38) Safety Study in Multiple Myeloma / NCT00574288", ClinicalTrials.gov, (20180427), XP055858034
OPPOSITION- LEVEQUE, D., "Subcutaneous administration of anticancer agents", Anticancer Research, (20140000), vol. 34, no. 4, pages 1579 - 1586, XP055344175
OPPOSITION- Nahi Hareth, Et Al, "An open-label, dose-escalation phase 1b study of subcutaneous daratumumab with recombinant human hyaluronidase in patients with relapsed or refractory multiple myeloma (PAVO)", Journal of Clinical Oncology, (20160520), pages 1 - 4, XP055857955
OPPOSITION- Ortolani, C., "CD38 Antigen", FLOW CYTOMETRY OF HEMATOLOGICAL MALIGNANCIES 1st Edition, Blackwell Publishing , (20110101), pages 68 - 70, XP055858004
OPPOSITION- ORTOLANI, C., "CD 38 Antigen", Flow Cytometry of Hematological Malignancies, (20110000), pages 68 - 70, XP055858004
OPPOSITION- "Phase 3 COLUMBA study investigating a subcutaneous formulation of DARZALEX® (daratumumab) showed non-inferiority to intravenous administration in patients with relapsed/refractory multiple mveloma", Press release, (20190000), XP093012138
OPPOSITION- PHIPPS, C. et al., "Daratumumab and its potential in the treatment of multiple myeloma: overview", Therapeutic Advances in Hematology, (20150000), vol. 6, no. 3, pages 120 - 127, XP055858013
OPPOSITION- PIVOT, X. et al., "Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized", Annals of Oncology, (20140000), vol. 25, no. 10, pages 1979 - 1987, XP055824228
OPPOSITION- P McLaughlin , A J Grillo-López, B K Link, R Levy, M S Czuczman, M E Williams, M R Heyman, I Bence-Bruckler, C A White, F Cabanillas, V Jain, A D Ho, J Lister, K Wey, D Shen, B K Dallaire, "Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program", Journal of Clinical Oncology, US , (19980801), vol. 16, no. 08, doi:10.1200/JCO.1998.16.8.2825, ISSN 0732-183X, pages 2825 - 2833, XP001027531
OPPOSITION- "Proteinarzneistoffe - Sensibel und stressanfallia", Pharmazeutische Zeitung, (20110000), vol. 156
OPPOSITION- Raritan, N.J, "Janssen Initiates Rolling Submission of Biologic License Application (BLA) for daratumumab with U.S. FDA for the Treatment of Multiple Myeloma | Johnson & Johnson", News Releases, (20150605), pages 1 - 3, News Releases, URL: https://www.jnj.com/media-center/press-releases/janssen-initiates-rolling-submission-of-biologic-license-application-bla-for-daratumumab-with-us-fda-for-the-treatment-of-multiple-myeloma, (20211102), XP055856903
OPPOSITION- SALAR, A. et al., "Comparison of Subcutaneous Versus Intravenous Administration of Rituximab As Maintenance Treatment for Follicular Lymphoma: Results From a Two-Stage, Phase IB Study", Journal of Clinical Oncology, (20140000), vol. 32, no. 17, pages 1782 - 1791, XP055858042
OPPOSITION- Salar Antonio, Avivi Irit, Bittner Beate, Bouabdallah Reda, Brewster Mike, Catalani Olivier, Follows George, Haynes Andrew, Hourcade-Potelleret Florence, Janikova Andrea, Larouche Jean-François, Mcintyre Christine, Pedersen Michael, Pereira Juliana, Sayyed Pakeeza, Shpilberg Ofer, Tumyan Gayane, "Comparison of Subcutaneous Versus Intravenous Administration of Rituximab As Maintenance Treatment for Follicular Lymphoma: Results From a Two-Stage, Phase IB Study", Journal of Clinical Oncology, (20140000), vol. 32, no. 17, pages 1782 - 1791, XP055858042
OPPOSITION- SONDERGELD, P. et al., "Monoclonal Antibodies in Myeloma", Clin Adv Hematol Oncol, (20150000), vol. 13, no. 9, pages 599 - 609, XP055858016
OPPOSITION- ZÁDNÍKOVÁ et al., "The degradation of hyaluronan in the skin", Biomolecules, (20220000), vol. 12, no. 251, pages 1 - 17, XP093013793
OPPOSITION- WANG, W. et al., "Antibody Structure Instability, and Formulation", Journal of Pharmaceutical Sciences, (20070000), vol. 96, no. 1, doi:10.1002/jps.20727, pages 1 - 26, XP009084505
OPPOSITION- Colson Kathleen, "Treatment-related symptom management in patients with multiple myeloma: a review", Supportive Care in Cancer, Berlin/Heidelberg, (20150203), vol. 23, no. 5, doi:10.1007/s00520-014-2552-1, ISSN 0941-4355, pages 1431 - 1445, XP035476439
OPPOSITION- WASSERMAN RL, "Progress in gammaglobulin therapy for immunodeficiency: from subcutaneous to intravenous infusions and back again", J Clin Immunol, (20121200), vol. 32, no. 6, doi:10.1007/s10875-012-9740-x, pages 1153 - 64, XP035153753
OPPOSITION- WASSERMAN, R.L., "Progress in gammaglobulin therapy for immunodeficiency: from subcutaneous to intravenous infusions and back again", Journal of Clinical Immunology, (20120000), vol. 32, no. 6, doi:10.1007/s10875-012-9740-x, pages 1153 - 1164, XP035153753
OPPOSITION- MOREAU et al., "Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma", Drugs, (20070000), vol. 76, no. 8, pages 853 - 867, XP093012463
OPPOSITION- Moreau Philippe, Et Al., "Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma", Drugs, Adis International Ltd., NZ, NZ , (20160501), vol. 76, no. 8, doi:10.1007/s40265-016-0573-4, ISSN 0012-6667, pages 853 - 867, XP093012463
OPPOSITION- Maury M, Murphy K, Kumar S, Mauerer A, Lee G, "Spray-drying of proteins: effects of sorbitol and trehalose on aggregation and FT-IR amide I spectrum of an immunoglobulin G", European Journal of Pharmaceutics and Biopharmaceutics, (20050000), pages 251 - 261, XP025317735
OPPOSITION- WARNE, N.W., "Development of high concentration protein biopharmaceuticals: The use of", European Journal of Pharmaceutics and Biopharmaceutics, (20110000), vol. 78, no. 2, doi:10.1016/j.ejpb.2011.03.004, pages 208 - 212, XP055534222
OPPOSITION- Wasserman Richard L., Melamed Isaac, Stein Mark R., Gupta Sudhir, Puck Jennifer, Engl Werner, Leibl Heinz, Mccoy Barbara, Empson Victoria G., Gelmont David, Schiff Richard I., "Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency", Journal of Allergy and Clinical Immunology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20121001), vol. 130, no. 4, doi:10.1016/j.jaci.2012.06.021, ISSN 0091-6749, pages 951 - 957.e11, XP093235882
OPPOSITION- Strickley Robert G., Lambert William J., "A review of Formulations of Commercially Available Antibodies", Journal of Pharmaceutical Sciences, (20210000), pages 2590 - 2608, XP055799313
OPPOSITION- DAVIES, A. et al., "Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study", Lancet Oncology, (20140000), vol. 15, pages 343 - 352, XP055857954
OPPOSITION- Davies Andrew, Merli Francesco, Mihaljevic Biljana, Siritanaratkul Noppadol, Solal-Céligny Phillippe, Barrett Martin, Berge Claude, Bittner Beate, Boehnke Axel, Mcintyre Christine, Macdonald David, "Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study(Suplementary appendix)", The Lancet Oncology, AMSTERDAM, NL , (20140301), doi:10.1016/S1470-2045(14)70005-1, pages 1 - 8, XP093090638
OPPOSITION- L D Piro , C A White, A J Grillo-López, N Janakiraman, A Saven, T M Beck, C Varns, S Shuey, M Czuczman, J W Lynch, J E Kolitz, V Jain, "Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma.", Annals of oncology, (19990601), vol. 10, no. 6, doi:10.1023/a:1008389119525, pages 655 - 661, XP002485834
OPPOSITION- SHPILBERG et al., "Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase", British Journal of Cancer, (20130309), vol. 109, doi:10.1038/bjc.2013.371, pages 1556 - 1561, XP002782443
OPPOSITION- SHPILBERG, O. et al., "Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase", British Journal of Cancer, (20130000), vol. 109, no. 6, doi:10.1038/bjc.2013.371, pages 1556 - 1561, XP002782443
OPPOSITION- Shpilberg O, Jackisch C, "Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase", British Journal of Cancer, (20130000), vol. 109, no. 6, pages 1556 - to 1561, XP002782443
OPPOSITION- Doessegger Lucette, Banholzer Maria Longauer, "Clinical development methodology for infusion-related reactions with monoclonal antibodies", Clinical & Translational Immunology, vol. 4, no. 7, doi:10.1038/cti.2015.14, XP093013271
OPPOSITION- OCIO, E. M. et al., "New drugs and novel mechanisms of action in multiple myeloma", Leukemia, (20130000), vol. 28, no. 3, doi:10.1038/leu.2013.350, pages 525 - 542, XP037787118
OPPOSITION- LONIAL, S. et al., "Monoclonal antibodies '' in the treatment of multiple myeloma: current status and", Leukemia, (20160000), vol. 30, doi:10.1038/leu.2015.223, pages 526 - 535, XP055496710
OPPOSITION- BITTNER, B. et al., "Non-clinical pharmacokinetic/pharmacodynamic and early clinical studies supporting development of a novel subcutaneous formulation for the monoclonal antibody rituximab", Drug Research, (20140000), vol. 64, no. 11, doi:10.1055/s-0033-1363993, pages 569 - 575, XP055857994
OPPOSITION- Bittner B., Richter W., Hourcade-Potelleret F., Herting F., Schmidt J., "Non-Clinical Pharmacokinetic/Pharmacodynamic and Early Clinical Studies Supporting Development of a Novel Subcutaneous Formulation for the Monoclonal Antibody Rituximab", Drug Research, (20140000), vol. 64, pages 569 - 575, XP055857994
OPPOSITION- JACKISCH C et al., "Subcutaneous Administration of Monoclonal Antibodies in Oncology", Geburtshilfe Frauenheilkd, (20140400), vol. 74, no. 4, doi:10.1055/s-0034-1368173, pages 343 - 349, XP055344155
OPPOSITION- JACKISCH, C. et al., "Subcutaneous administration of monoclonal antibodies in oncology", Geburtshilfe und Frauenheilkunde, (20140000), vol. 74, no. 04, doi:10.1055/s-0034-1368173, pages 343 - 349, XP055344155
OPPOSITION- Jackisch C., Müller V., Maintz C., Hell S., Ataseven B., "Subcutaneous Administration of Monoclonal Antibodies in Oncology", Geburtshilfe und Frauenheilkunde, (20140000), vol. 74, no. 4, pages 343 - 349, XP055573377
OPPOSITION- Henk M Lokhorst; Torben Plesner; Jacob P Laubach; Hareth Nahi; Peter Gimsing; Markus Hansson; Monique C Minnema; Ulrik Lassen; Jakub Krejcik; Antonio Palumbo; Niels W C J Van De Donk; Tahamtan Ahmadi; Imran Khan; Clarissa M Uhlar; Jianping Wang; Kate Sasser A; Nedjad Losic; Steen Lisby; Linda Basse; Nikolai Brun; Paul G Richardson, "Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma", The New England journal of medicine, (20150000), vol. 373, no. 13, pages 1207 - 1219, XP055413700
OPPOSITION- LOKHORST HM et al., "Targeting CD 38 with Daratumumab Monotherapy in Multiple Myeloma", N Engl J Med, vol. 373, no. 13, doi:10.1056/NEJMoa1506348, (20150000), pages 1207 - 19, (20150826), XP055413700
OPPOSITION- LOKHORST, H. M. et al., "Targeting CD 38 with daratumumab monotherapy in multiple myeloma", New England Journal of Medicine, (20150000), vol. 373, no. 13, doi:10.1056/NEJMoa1506348, pages 1207 - 1219, XP055413700
OPPOSITION- Yamamoto Hayato, Tobisawa Yuki, Inubushi Toshihiro, Irie Fumitoshi, Ohyama Chikara, Yamaguchi Yu, "A mammalian homolog of the zebrafish transmembrane protein 2 (TMEM2) is the long-sought-after cell-surface hyaluronidase", Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, US, US , (20170301), vol. 292, no. 18, doi:10.1074/jbc.M116.770149, ISSN 0021-9258, pages 7304 - 7313, XP093012918
OPPOSITION- Zojer Niklas, Kirchbacher Klaus, Vesely Michael, Hübl Wolfgang, Ludwig Heinz, "Rituximab treatment provides no clinical benefit in patients with pretreated advanced multiple myeloma", Leukemia & Lymphoma, (20060000), vol. 47, no. 6, pages 1103 - 1109, XP093013767
OPPOSITION- ZAGOURI, FLORA et al., "Emerging antibodies for the treatment of multiple myeloma", Expert opinion on emerging drugs, (20160000), vol. 21, no. 2, doi:10.1080/14728214.2016.1186644, pages 225 - 37, XP055294821
OPPOSITION- KNOWLES et al., "Safety of recombinant human hyaluronidase PH 20 for subcutaneous drug delivery", Expert Opin Drug Deliv, (20211100), vol. 18, no. 11, doi:10.1080/17425247.2021.1981286, pages 1673 - 1685, XP055905786
OPPOSITION- KNOWLES, S.P. et al., "Safety of recombinant human hyaluronidase PH 20 for subcutaneous drug delivery", Expert Opinion on Drug Delivery, (20210000), vol. 18, no. 11, doi:10.1080/17425247.2021.1981286, pages 1673 - 1685, XP055905786
OPPOSITION- Jackisch C., Kim S.-B., Semiglazov V., Melichar B., Pivot X., Hillenbach C., Stroyakovskiy D., Lum B.L., Elliott R., Weber H.A., Ismael G., "Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study", Annals of Oncology, Kluwer Dordrecht, NL, NL , (20150201), vol. 26, no. 2, doi:10.1093/annonc/mdu524, ISSN 0923-7534, pages 320 - 325, XP093012921
OPPOSITION- ARTHUR, A. O., "Innovations in subcutaneous infusions", Journal of Infusion Nursing, (20150000), vol. 38, no. 3, doi:10.1097/NAN.0000000000000099, pages 179 - 187, XP009510495
OPPOSITION- VAN DE DONK, NIELS W C J et al., "Monoclonal antibodies targeting CD 38 in hematological malignancies and beyond", Immunological reviews, (20160000), vol. 270, no. 1, doi:10.1111/imr.12389, pages 95 - 112, XP071456198
OPPOSITION- Thomas A. Davis , Antonio J. Grillo-López , Christine A. White , Peter McLaughlin , Myron S. Czuczman , Brian K. LinkDavid G. Maloney , Robin L. Weaver , Jay Rosenberg , Ronald Levy, "Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin’s Lymphoma: Safety and Efficacy of Re-Treatment", Journal of Clinical Oncology, (20000917), vol. 18, no. 17, doi:10.1200/JCO.2000.18.17.3135, pages 3135 - 3143, XP093090178
OPPOSITION- ROSENGREN, SANNA et al., "Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration", The AAPS journal vol, (20150000), vol. 17, no. 5, doi:10.1208/s12248-015-9782-0, pages 1144 - 56, XP055856917
OPPOSITION- ROSENGREN S et al., "Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration", AAPS J, vol. 17, no. 5, doi:10.1208/s12248-015-9782-0, (20150000), pages 1144 - 56, (20150513), XP055856917
OPPOSITION- ROSENGREN, S. et al., "Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration", The AAPS Journal, (20150000), vol. 17, no. 5, doi:10.1208/s12248-015-9782-0, pages 1144 - 1156, XP055856917
OPPOSITION- FROST, G. I., "Recombinant human hyaluronidase (rHuPH20): '' an enabling platform for", Expert Opinion on Drug Delivery, (20070000), vol. 4, no. 4, doi:10.1517/17425247.4.4.427, pages 427 - 440, XP008177677
OPPOSITION- CHUNG, C.H., "Managing Premedications and the Risk for Reactions to Infusional Monoclonal Antibody Thera", The Oncologist, (20080000), vol. 13, doi:10.1634/theoncologist.2008-0012, pages 725 - 732, XP055307522
OPPOSITION- HAMIZI, S. et al., "Subcutaneous trastuzumab: development of a new formulation for treatment of - early breast cancer", OncoTargets and Therapy, (20130000), vol. 6, doi:10.2147/OTT.S27733, page 89, XP055476980
OPPOSITION- HAMIZI, S. et al., "Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancer", OncoTargets and Therapy, (20130000), vol. 6, doi:10.2147/OTT.S27733, pages 89 - 94, XP055476980
OPPOSITION- Žádníková Petra, Šínová Romana, Pavlík Vojtěch, Šimek Matěj, Šafránková Barbora, Hermannová Martina, Nešporová Kristina, Velebný Vladimír, "The Degradation of Hyaluronan in the Skin", Biomolecules, (20220203), vol. 12, no. 2, doi:10.3390/biom12020251, page 251, XP093012917
OPPOSITION- De Weers Michel, Tai Yu-Tzu, Van Der Veer Michael S., Bakker Joost M., Vink Tom, Jacobs Daniëlle C. H., Oomen Lukas A., Peipp Matthias, Valerius Thomas, Slootstra Jerry W., Mutis Tuna, Bleeker Wim K., Anderson Kenneth C., Lokhorst Henk M., Van De Winkel Jan G. J., Parren Paul W. H. I., "Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors", The Journal of Immunology, (20110000), pages 1840 - 1848, XP055005408

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents